• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA: NiMS markets therapeutic vibrator for unapproved uses

FDA: NiMS markets therapeutic vibrator for unapproved uses

March 28, 2011 By MassDevice staff

FDA

The FDA sent a warning letter to Non-Invasive Monitoring Systems Inc. (OTC:NIMU) alleging that the company markets its therapeutic vibrator for uses not approved by the federal watchdog agency.

The Miami, Fla.-based company’s Exer-Rest “whole body periodic acceleration system” is a Class I exempt device, according to the company, meaning it doesn’t need to undergo the pre-market studies required for 510(k) clearance or the more rigorous pre-market approval process for medical devices.

But the FDA claims the company is marketing the device for indications that would require both types of approval. A device qualifies for "Class I" exemption "when it is intended for relaxing muscles and relieving minor aches and pains," according to the FDA’s letter. The warning notes that the company website’s "Study Support" section indicates that the Exer-Rest "may be used during CPR, as ‘cardioprotective preconditioning,’ for brain damage reduction in ischemic strokes, for asphyxia, for enhancing brachial endothelial function, for cardiovascular disease, for asthma, and for fibromyalgia."

The FDA ordered the company to immediate remove the offending language from its site.

The "Study Support" section of the company’s website no longer lists the information that the FDA took issue with, but a March 9 cached copy of the webpage on Google’s servers includes the statement "Science supports Whole Body Periodic Acceleration for safe and effective therapy," which is followed by six studies on the device involving CPR, each of which is still stored on the company’s server.

NiMS inked a deal in September 2009 with the Naval Medical Research Center in Silver Springs, Md., to evaluate the Exer-Rest for patients with traumatic brain injury.

The release describes the Exer-Rest as an "FDA listed medical device intended as an aid to temporarily increase local circulation, to provide temporary relief of minor aches and pains, to reduce morning stiffness and to provide local muscle relaxation." The Exer-Rest is also approved in the United Kingdom, European Union, Canada and Mexico "as an aid to increasing circulation and for increasing joint mobility," according to the company.

Filed Under: Food & Drug Administration (FDA), News Well Tagged With: Non-Invasive Monitoring Systems Inc., Warning Letter

More recent news

  • Data backs DermaSensor skin cancer detection device
  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy